Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study

被引：13

作者：

Molina, Blanca ^{[1
]}

Gonzalez Vicent, Marta ^{[1
]}

Herrero, Blanca ^{[1
]}

Deltoro, Natalia ^{[1
]}

Ruiz, Julia ^{[1
]}

Perez Martinez, Antonio ^{[2
]}

Diaz, Miguel A. ^{[1
]}

机构：

[1] Hosp Nino Jesus, Stem Cell Transplant Unit, Avda Menendez Pelayo 65, Madrid 28009, Spain

[2] Hosp La Paz, Hematol Oncol, Madrid, Spain

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2019年 / 25卷 / 01期

关键词：

Allogeneic stem cell transplantation; Leukemia; Relapse; Chronic graft-versus-host disease (GVHD); Children; Risk score; VERSUS-HOST-DISEASE; PEDIATRIC-PATIENTS; REDUCED INTENSITY; OUTCOMES; BLOOD; MORTALITY; CRITERIA; IMPACT; GVHD;

D O I：

10.1016/j.bbmt.2018.08.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment for high-risk hematological malignancies in the pediatric population, but relapse remains the leading cause of death. We analyzed risk factors associated with relapse. Data from 353 allo-HSCTs from 1989 to 2015 in our center were studied retrospectively. We performed a multivariate analysis of pre- and postransplantation variables and developed a predictive risk score for relapse using the significant factors in this training cohort. The results were confirmed in a validation cohort of 90 allo-HSCTs done in our institution from 2016 to the present. A total of 104 patients relapsed after allo-HSCT, with a relapse cumulative incidence of 31 +/- 2%. In multivariate analysis, only 2 variables influenced relapse: disease phase (advanced versus early, HR, 2.84; 95% CI, 1.76 to 4.57; P= .001) and presence of chronic graft-versus-host disease (GVHD) (acute GVHD versus chronic GVHD [HR, 4.27; 95% CI, 1.99 to 9.15; P= .0001] and no GVHD versus chronic GVHD [HR, 6.86; 95% CI, 3.63 to 12.97] P= .0001]. Applying the personalized risk score (0 to 3), the relapse cumulative incidence was 70 +/- 5% in patients with a score of 3 (without GVHD and in the advanced phase) compared with 6 +/- 4% in patients with a score of 0 (with chronic GVHD and in an early phase). This score has been verified in the validation set. With a median follow-up of 54 months, the disease-free survival (DFS) and overall survival rate were 37 +/- 3% and 45 +/- 4%, respectively. The association of GVHD with the graft-versus-leukemia effect is clearly established in our study, and the form of GVHD associated with less relapse and the best DFS is the classical form of chronic GVHD according to the National Institutes of Health classification. The proposed relapse risk score was validated in an independent cohort and allows personalization of the prognosis. (C) 2018 American Society for Blood and Marrow Transplantation.

引用

页码：100 / 106

页数：7

共 27 条

[1] Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group [J].

Bader, Peter ;

Kreyenberg, Hermann ;

Henze, Guenter H. R. ;

Eckert, Cornelia ;

Reising, Miriam ;

Willasch, Andre ;

Barth, Andrea ;

Borkhardt, Arndt ;

Peters, Christina ;

Handgretinger, Rupert ;

Sykora, Karl-Walter ;

Holter, Wolfgang ;

Kabisch, Hartmut ;

Klingebiel, Thomas ;

von Stackelberg, Arend .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :377-384

[2] National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee [J].

Bishop, Michael R. ;

Alyea, Edwin P., III ;

Cairo, Mitchell S. ;

Falkenburg, J. H. Frederik ;

June, Carl H. ;

Kroeger, Nicolaus ;

Little, Richard F. ;

Miller, Jeffrey S. ;

Pavletic, Steven Z. ;

Porter, David L. ;

Riddell, Stanley R. ;

van Besien, Koen ;

Wayne, Alan S. ;

Weisdorf, Daniel J. ;

Wu, Roy S. ;

Giralt, Sergio .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (04) :443-454

[3] Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation [J].

Bitan, Menachem ;

Ahn, Kwang Woo ;

Millard, Heather R. ;

Pulsipher, Michael A. ;

Abdel-Azim, Hisham ;

Auletta, Jeffery J. ;

Brown, Valerie ;

Chan, Ka Wah ;

Diaz, Miguel Angel ;

Dietz, Andrew ;

Vincent, Marta Gonzalez ;

Guilcher, Gregory ;

Hale, Gregory A. ;

Hayashi, Robert J. ;

Keating, Amy ;

Mehta, Parinda ;

Myers, Kasiani ;

Page, Kristin ;

Prestidge, Tim ;

Shah, Nirali N. ;

Smith, Angela R. ;

Woolfrey, Ann ;

Thiel, Elizabeth ;

Davies, Stella M. ;

Eapen, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) :1523-1530

[4] Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens [J].

Bitan, Menachem ;

He, Wensheng ;

Zhang, Mei-Jie ;

Abdel-Azim, Hisham ;

Ayas, Mouhab Fakhreddine ;

Bielorai, Bella ;

Carpenter, Paul A. ;

Cairo, Mitchell S. ;

Angel Diaz, Miguel ;

Horan, John T. ;

Jodele, Sonata ;

Kitko, Carrie L. ;

Schultz, Kirk R. ;

Kletzel, Morris ;

Kasow, Kimberly A. ;

Lehmann, Leslie E. ;

Mehta, Parinda A. ;

Shah, Nirali ;

Pulsipher, Michael A. ;

Prestidge, Tim ;

Seber, Adriana ;

Shenoy, Shalini ;

Woolfrey, Ann E. ;

Yu, Lolie C. ;

Davies, Stella M. .

BLOOD, 2014, 123 (10) :1615-1620

[5] Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia [J].

Boyiadzis, Michael ;

Arora, Mukta ;

Klein, John P. ;

Hassebroek, Anna ;

Hemmer, Michael ;

Urbano-Ispizua, Alvaro ;

Antin, Joseph H. ;

Bolwell, Brian J. ;

Cahn, Jean-Yves Y. ;

Cairo, Mitchell S. ;

Cutler, Corey S. ;

Flowers, Mary E. ;

Gale, Robert P. ;

Herzig, Roger ;

Isola, Luis M. ;

Jacobsohn, David A. ;

Jagasia, Madan H. ;

Klumpp, Thomas R. ;

Lee, Stephanie J. ;

Petersdorf, Effie W. ;

Santarone, Stella ;

Spellman, Stephen R. ;

Schouten, Harry C. ;

Verdonck, Leo F. ;

Wingard, John R. ;

Weisdorf, Daniel J. ;

Horowitz, Mary M. ;

Pavletic, Steven Z. .

CLINICAL CANCER RESEARCH, 2015, 21 (09) :2020-2028

[6]

Cho BS, 2012, BIOL BLOOD MARROW TR, V18, P1

[7] Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts [J].

Diaz, M. A. ;

Perez-Martinez, A. ;

Herrero, B. ;

Deltoro, N. ;

Martinez, I. ;

Ramirez, M. ;

Abad, L. ;

Sevilla, J. ;

Merino, E. ;

Ruiz, J. ;

Vicario, J. L. ;

Gonzalez-Vicent, M. .

BONE MARROW TRANSPLANTATION, 2016, 51 (09) :1211-1216

[8] Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH) [J].

Diaz, MA ;

Gonzalez-Vicent, M ;

Gonzalez, ME ;

Verdeguer, A ;

Martinez, A ;

Perez-Hurtado, M ;

Badell, I ;

de la Rubia, J ;

Bargay, J ;

de Arriba, F ;

Diez, JL ;

Caballero, D ;

Madero, L ;

Brunet, S .

BONE MARROW TRANSPLANTATION, 2005, 36 (09) :781-785

[9] Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients [J].

Diaz, MA ;

Vicent, MG ;

Gonzalez, ME ;

Verdeguer, A ;

de la Rubia, J ;

Bargay, J ;

de Arriba, F ;

Diez, JL ;

Caballero, D ;

Madero, L ;

Brunet, S .

BONE MARROW TRANSPLANTATION, 2004, 34 (05) :433-438

[10] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].

Filipovich, AH ;

Weisdorf, D ;

Pavletic, S ;

Socie, G ;

Wingard, JR ;

Lee, SJ ;

Martin, P ;

Chien, J ;

Przepiorka, D ;

Couriel, D ;

Cowen, EW ;

Dinndorf, P ;

Farrell, A ;

Hartzman, R ;

Henslee-Downey, J ;

Jacobsohn, D ;

McDonald, G ;

Mittleman, B ;

Rizzo, JD ;

Robinson, M ;

Schubert, M ;

Schultz, K ;

Shulman, H ;

Turner, M ;

Vogelsang, G ;

Flowers, MED .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956

← 1 2 3 →